Figure 2.

Immune evasion by SARS-CoV-2 Delta-Omicron (XD) recombinant lineage. (A) Particles bearing the indicated S proteins were incubated with plasma from individuals that received two doses of the Cormirnaty/BNT162b2 vaccine, before being added to Vero cells. Pseudotype entry was normalized against the respective control (set as 0% inhibition). Further, the neutralizing titer that reduced pseudotype entry by 50% (NT50) was calculated (of note, samples with NT50 < 6.25 were considered negative and values were manually set as 1). In addition, the median fold change in NT50 was calculated (for comparison of BA.1_pp and XD_pp neutralization, only samples with NT50 (BA.1_pp) > 6.25 were selected). Presented are the geometric mean NT50 data (indicated by black lines and numerical values). (B) The experiment was performed as described in panel A but plasma from ten individuals that received three doses of the Cormirnaty/BNT162b2 vaccine was used. (C) The experiment was performed as described in panel A but serum from seven individuals that received three doses of the Comirnaty/BNT162b2 vaccine and that were infected during the “Delta wave” in Germany was used. (D) The experiment was performed as described in panel A but plasma from nine individuals that received three doses of the Comirnaty/BNT162b2 vaccine and that were infected during the “Omicron wave” in Germany was used. Statistical analysis was performed using Kruskal–Wallis analysis with Dunns’ multiple comparison test (ns, p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01). Please also see Figure S3 for individual neutralization data.